A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

NCT01196208 NO_LONGER_AVAILABLE

The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001

Details

Lead sponsor	Seagen Inc.
Status	NO_LONGER_AVAILABLE

Conditions

• Disease, Hodgkin
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, Non-Hodgkin
• Lymphoma, T-Cell, Cutaneous

Interventions

• brentuximab vedotin

Countries

France, Italy, Russia, Belgium, Serbia, United Kingdom, Germany, Hungary, Poland, Romania, Switzerland, Bulgaria, Australia, United States, Spain